Anticancer activities of orally administered menogaril against human stomach and breast cancers implanted in nude mice.

Abstract

The therapeutic effects of orally administered menogaril, a semisynthetic analog of the anthracycline antibiotic nogalamycin, were studied on a panel of human stomach and breast cancer xenografts. The maximum tolerated dose (200 mg/kg) of menogaril was administered 3 times every 4 days and its growth-inhibitory effects on subcutaneously implanted tumors in nude mice were evaluated. Menogaril significantly retarded the growth of 3 out of 7 stomach cancers, SC-2, SC-9 and 4-1ST, and 3 out of 4 breast cancers, H-31, MC-2 and MX-1, with overall response rates of 43 and 75% for stomach and breast cancers, respectively. Some of these relatively responsive cancers were also treated by daily oral administration for 5 consecutive days, but the anticancer effects of the intermittent administration seemed to be better. These results suggest that menogaril may be effective against stomach and breast cancers when orally administered.

• Authors: M Inaba, S Sato, T Yamori, T Tashiro, Y Ohnishi, K Maruo, Y Ueyama, T Tsuruo
• Journal: Anticancer research (Anticancer Res) 1992 Nov-Dec Vol. 12 Issue 6B Pg. 1953-6 ISSN: 0250-7005 [Print] Greece
• PMID: 1295442 (Publication Type: Journal Article)

Chemical References

• Menogaril

Topics

• Administration, Oral
• Animals
• Breast Neoplasms (drug therapy, pathology)
• Female
• Humans
• Menogaril (administration & dosage, therapeutic use)
• Mice
• Mice, Nude
• Neoplasm Transplantation
• Stomach Neoplasms (drug therapy, pathology)
• Transplantation, Heterologous
• Tumor Cells, Cultured